---
document_datetime: 2023-09-21 17:12:26
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps/focetria-epar-procedural-steps-taken-authorisation_en.pdf
document_name: focetria-epar-procedural-steps-taken-authorisation_en.pdf
version: success
processing_time: 0.5369641
conversion_datetime: 2025-12-18 10:18:09.660493
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## BACKGROUND INFORMATION ON THE PROCEDURE

## 1. Submission of the dossier

The applicant Chiron S.r.l. submitted on  12 January 2006 an application for Marketing Authorisation to  the  European  Medicines  Agency  (EMEA) for  Focetria,  through the centralised  procedure  falling within the Article 3(1) and point 1 of Annex of Regulation (EC) No 726/2004. The applicant's name Chiron S.r.l was changed into Novartis Vaccines and Diagnostics S.r.l in October 2006 further to the Novartis acquisition. As a consequence the applicant now of this application is Novartis Vaccines and Diagnostics S.r.l.

- During  the  meeting  on  24-27  April  2006,  the  CHMP  agreed  on  the  consolidated  List  of Questions to be sent to the applicant. The final consolidated List of Questions was sent to the applicant on  27 April 2006.

Medicinal product no longer authorised The legal basis for this application refers to: Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application Scientific Advice: The applicant received Scientific Advice from the CHMP on 15 December 2006 (EMEA/420093/2005). The Scientific Advice pertained to quality, non-clinical and clinical aspects of the dossier. Licensing status: The product was not licensed in any country at the time of submission of the application. The Rapporteur and Co-Rapporteur appointed by the CHMP and the evaluation teams were: Rapporteur: Dr Pasqualino Rossi Co-Rapporteur: Dr Frits Lekkerkerker 2. Steps taken for the assessment of the product · The application was received by the EMEA on 12 January 2006. · Accelerated Assessment procedure was agreed-upon by CHMP on 15 December 2005. · The procedure started on 1 February 2006. · The Rapporteur's first Assessment Report was circulated to all  CHMP  members  on 3 April 2006.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP members on 31 March 2006. In accordance with Article 6(3) of Regulation (EC) No. 726/2004, the Rapporteur and Co-Rapporteur declared that they had completed their assessment report in less than 80 days. · The BWP discussed Focetria during their meeting on 19-20 April 2006 and adopted a BWP report to the CHMP.

- The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on 14 July 2006 and 24 October 2006.
- The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Questions to all CHMP members on  5 January 2007.

<div style=\"page-break-after: always\"></div>

- The VWP discussed Focetria during their meeting on 9-11 January 2007 and adopted a Report to the CHMP.
- The BWP discussed Focetria during their meeting on 15-16 January 2007 and adopted a Report to the CHMP.
- During the CHMP meeting on 22-24 January 2007, the CHMP agreed on a List of Outstanding Issues to be addressed in writing by the applicant
- The applicant submitted the responses to the CHMP  List  of Outstanding Issues on 30 January 2007.
- Medicinal product no longer authorised · The Rapporteurs circulated the Joint Assessment Report on the applicant's responses to the List of Outstanding Issues to all CHMP members on  7 February 2007. · The  BWP  discussed  Focetria  during  their  meeting  on  12-14  February  2007  and  adopted  a Report to the CHMP · During  the  meeting  on    19-22  February  2007,  the  CHMP,  in  the  light  of  the  overall  data submitted  and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for granting a Marketing Authorisation under exceptional circumstances to Focetria on 22 February 2007. The applicant provided the letter of undertaking on the specific obligations and follow-up measures to be fulfilled post-authorisation on 22 February 2007.

<!-- image -->